Proteolix Announces the Appointment of John Scarlett, M.D., President and CEO
...in 2002. While there, he led the company through the approval and commercialization of Increlex(R) and the commercialization of Somatuline Depot(R). tercica merged in late 2008 with Ipsen, S.A. From 1993 through 2001, Dr. Scarlett served as Chief Executive Officer of Sensus Drug Development Corporation, w...Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
...e revenues lost from our withdrawal of IPLEX(TM) in the short stature market pursuant to the terms of our settlement agreement with Genentech Inc. and tercica Inc., entered into in March 2007. The net loss for the 12 months ended December 31, 2008 was $15.7 million or $0.13 per share, compared to $20.0 ...Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
...e revenues lost from our withdrawal of IPLEX(TM) in the short stature market pursuant to the terms of our settlement agreement with Genentech Inc. and tercica Inc. entered into in 2007. The net loss for the six months ended June 30, 2008 was $9.5 million, or $0.08 per share, compared to $12.8 million, or $...Insmed Announces First Quarter 2008 Financial Results
...lost from our withdrawal of IPLEX(TM) in the short stature market pursuant to the terms of our March 2007 Settlement Agreement with Genentech Inc. and tercica Inc., and the absence of license income from our agreement with Napo Pharmaceuticals Inc., ("Napo") from which we received a milestone payment in the ...Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
... Hyperion, Mr. Rivera was Senior Vice President of Commercial Operations at tercica where he was responsible for developing and overseeing Tercica's global com...e President, Global Sales was most recently the Vice President of Sales for tercica Inc. In this capacity, he created and implemented a national sales program ...